D2P Pharma located in Bois-Guillaume (Seine-Maritime), ZAC Leader – rue Gustave Eiffel

The inspection of D2P Pharma's facility in Bois-Guillaume, Seine-Maritime, France, conducted on May 3, 2024, revealed significant non-conformities and breaches. A letter was sent to the establishment on October 8, 2024, highlighting the issues that were not satisfactorily addressed by the company. The main purpose of this notification is to enforce compliance with French health regulations, specifically articles L. 5311-1, L. 5312-4-3, and L. 5313-1 of the Public Health Code. Important compliance considerations include: * Ceasing the exportation or direct export of specific medicines * Implementing robust systems for controlling medication sales * Ensuring temperature control in storage facilities * Establishing a system for monitoring unusual medication sales * Implementing secure methods for receiving controlled substances